** Shares of drug developer Rapt Therapeutics RAPT.O fall 42.4% to $1.66
** Co says based on recent feedback from the U.S. FDA it has stopped development of its drug Zelnecirnon, for eczema and asthma
** The decision follows a clinical hold placed on the drug's trial by the FDA in February after a serious case of liver injury in one of the patients
** Co says it will identify a new experimental therapy to develop in H1 2025
** Including session's move, stock down 93.4%
(Reporting by Puyaan Singh and Christy Santhosh)
((Puyaan.Singh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。